Key Takeaways
- Phase 2 trials used weekly subcutaneous survodutide doses from 2.4 mg to 6.0 mg, reached via a multi-week escalation starting as low as 0.3 mg to 0.6 mg.
- The 6.0 mg weekly dose produced approximately 14.9% mean body weight reduction at 46 weeks in the primary Phase 2 obesity trial (roughly 387 participants).
- Survodutide targets both the GLP-1 receptor and the glucagon receptor with approximately balanced potency, distinguishing it mechanistically from pure GLP-1 agonists like semaglutide.
- As of May 2026, survodutide is an investigational compound only. No approved dosing exists. Outside of clinical trials, any use is off-label research use.
- The biggest sourcing risk is peptide purity: mass-spec-verified COA with greater than 98% HPLC purity is the minimum credibility bar for any research-grade vial.
What is the survodutide dosage used in human trials?
Survodutide dosage in the pivotal Phase 2 obesity trial (NCT04667377, Boehringer Ingelheim) ranged from 2.4 mg to 6.0 mg given by subcutaneous injection once weekly. The trial enrolled approximately 387 adults with obesity or overweight plus comorbidities and ran 46 weeks. Four active dose arms were tested alongside placebo. Escalation from a starting dose of roughly 0.3 mg to 0.6 mg occurred over several months to build gastrointestinal tolerance before reaching the target maintenance dose. This is the core clinical data set available in open literature as of mid-2026.
Table of Contents
- Survodutide Dosing Chart by Phase
- How the Dual Receptor Mechanism Changes Dosing Logic
- Evidence Ledger: What the Data Actually Support
- What Most Pages Get Wrong About Survodutide Dosage
- Why the Escalation Rule Exists: The Chemistry
- Head-to-Head: Survodutide vs. Semaglutide vs. Tirzepatide
- Label and COA Literacy: Reading a Survodutide Vial
- Side Effects by Dose Band
- FAQ
- Sources
What does the survodutide dosing chart look like?
The table below reconstructs the escalation structure used across Phase 2 based on published and registered trial information. Exact week-by-week steps within each escalation block are not fully detailed in open literature; the structure below reflects the reported dose arms and general escalation approach described in trial publications and ClinicalTrials.gov registration.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →| Escalation Phase | Approximate Dose Range | Duration | Purpose |
|---|---|---|---|
| Initiation | 0.3 mg to 0.6 mg weekly | Weeks 1 to 4 | Establish GI tolerance, receptor down-titration baseline |
| Escalation 1 | 0.9 mg to 1.2 mg weekly | Weeks 5 to 8 | Progressive receptor loading |
| Escalation 2 | 1.8 mg to 2.4 mg weekly | Weeks 9 to 16 | Approach first clinical dose arm target |
| Maintenance low | 2.4 mg weekly | Through week 46 | Lowest maintenance arm in Phase 2 |
| Maintenance mid | 4.8 mg weekly | Through week 46 | Mid maintenance arm, favorable efficacy/tolerability ratio |
| Maintenance high | 6.0 mg weekly | Through week 46 | Highest Phase 2 dose, greatest weight loss, higher GI AE rate |
How does the dual receptor mechanism change dosing logic?
Survodutide (also called BI 456906) is a fatty-acid-conjugated synthetic peptide with roughly balanced agonist activity at both the GLP-1 receptor (GLP-1R) and the glucagon receptor (GCGR). This dual activity is the core pharmacological distinction from semaglutide or liraglutide, which are near-selective GLP-1R agonists.
GLP-1R activation suppresses appetite via hypothalamic signaling, slows gastric emptying, and augments glucose-dependent insulin secretion. These effects are well established across the GLP-1 drug class.
GCGR activation adds a separate metabolic layer. Glucagon receptor agonism increases energy expenditure by stimulating hepatic fatty acid oxidation, raises basal metabolic rate, and has direct effects on hepatic lipid metabolism that are relevant to MASH (metabolic dysfunction-associated steatohepatitis). It also carries a risk of increasing glucose levels if GLP-1R counterbalancing is insufficient.
The dosing implication is that escalation must manage two distinct receptor tolerability profiles simultaneously. The GLP-1 component drives nausea and vomiting at higher doses. The glucagon component at higher doses may affect fasting glucose, particularly in normoglycemic individuals. This is why dose escalation in Phase 2 was slow and stepwise: both receptor systems need time to reach a new homeostatic set point.
The fatty acid conjugation (similar in structural strategy to semaglutide's C-18 fatty diacid linker) is what extends half-life to approximately once-weekly duration by promoting albumin binding and slowing renal clearance. Without this modification, a bare GLP-1/glucagon peptide would have a half-life measured in minutes.
Evidence ledger: what does the data actually support at each dose?
| Claim | Best Evidence Type | Trial / Source | Effect Direction | Confidence |
|---|---|---|---|---|
| 6.0 mg weekly produces approx. 14.9% mean body weight loss at 46 weeks | Human Phase 2 RCT | Boehringer Ingelheim / NCT04667377, ~387 participants | Positive, clinically meaningful | Moderate (Phase 2 only; Phase 3 pending) |
| 4.8 mg weekly produces meaningful weight loss vs. placebo | Human Phase 2 RCT | Same trial | Positive | Moderate |
| Higher doses produce higher GI adverse event rates | Human Phase 2 RCT | Same trial, AE reporting | Dose-dependent increase in nausea/vomiting | High (consistent with GLP-1 class) |
| GCGR agonism improves MASH histology | Phase 2 RCT (separate MASH trial) | NCT05066178 | Positive signal in interim data | Low (interim, not fully published) |
| Dual GLP-1/GCGR mechanism increases energy expenditure vs. GLP-1 alone | Animal and mechanistic studies | Preclinical Boehringer literature, general dual-agonist literature | Positive in animal models | Low (not confirmed in human energy expenditure RCT) |
| Once-weekly dosing sufficient due to fatty acid half-life extension | Phase 1 PK data (not fully open-access) | Boehringer Ingelheim Phase 1 documentation | Consistent with once-weekly design | Moderate |
| Survodutide superior to semaglutide for weight loss | No head-to-head RCT published | None available | Unknown | Very Low |
What most pages get wrong about survodutide dosage
1. Treating Phase 2 doses as approved doses. The 2.4 to 6.0 mg weekly range is a research dose, not a prescription dose. Phase 2 trials are primarily designed to find a dose range for Phase 3, not to establish the final clinical dose. The approved dose, if the compound eventually gains approval, may be different.
2. Ignoring the glucagon receptor contribution to tolerability. Most summaries describe survodutide side effects as purely "GLP-1 class effects." The glucagon receptor agonism adds hepatic and metabolic effects, and may influence glycemic variability in non-diabetic users in ways that pure GLP-1 dosing guides do not account for.
3. Assuming mg-to-mg equivalence with semaglutide. Survodutide doses look much higher numerically (up to 6.0 mg vs. semaglutide 2.4 mg). This does not mean it is a "stronger" or "more dangerous" drug per milligram. Molecular weight, receptor selectivity ratios, formulation, and pharmacokinetics all differ. Direct numerical comparison without context is misleading.
4. Omitting the escalation requirement. Starting at the maintenance dose (even 2.4 mg) without escalation would predictably cause severe gastrointestinal adverse events. The escalation schedule is not optional; it is a pharmacological necessity because GLP-1R signaling triggers nausea before receptor adaptation occurs.
5. Claiming efficacy data from Phase 3 that does not yet exist. As of mid-2026, Phase 3 results are not publicly available. Any page claiming Phase 3-confirmed weight loss numbers for survodutide should be treated with skepticism.
Why does the escalation rule exist? The chemistry behind it
GLP-1 receptors in the gut (particularly on vagal afferents and enteroendocrine cells) mediate nausea through activation of area postrema neurons and altered gastric motility. When a GLP-1R agonist first arrives at high concentration, these peripheral receptors are not yet desensitized. Repeated exposure causes receptor internalization and downstream desensitization via beta-arrestin recruitment, reducing the nausea signal over weeks. This is the biological reason the escalation window typically spans 8 to 20 weeks across GLP-1 class drugs.
The fatty acid conjugation on survodutide creates a depot-like pharmacokinetic profile by promoting reversible albumin binding in plasma. The free (pharmacologically active) fraction is released slowly over days. This is chemically similar to the C-18 fatty diacid strategy used in semaglutide, where the linker slows renal filtration and extends half-life from minutes (for native GLP-1) to approximately 7 days. This is why splitting the dose or dosing more frequently than weekly provides no clinical rationale and would disrupt the designed plasma concentration curve.
Lyophilized peptide powder is more chemically stable than reconstituted solution because water is the primary reactant in both hydrolysis (breaking peptide bonds) and oxidation pathways. Once reconstituted, the peptide is vulnerable to aggregation, oxidation at susceptible residues, and temperature-driven denaturation. Reconstituted survodutide should be refrigerated and used within a timeframe consistent with the manufacturer's guidance, typically days to a few weeks. Visual cloudiness, particulate matter, or color change after reconstitution indicates degradation and the material should not be used.
Honest head-to-head: survodutide vs. semaglutide vs. tirzepatide
| Attribute | Survodutide | Semaglutide (Wegovy) | Tirzepatide (Zepbound) |
|---|---|---|---|
| Receptor targets | GLP-1R + GCGR (dual, approximately balanced) | GLP-1R (selective) | GLP-1R + GIPR (dual) |
| Approval status (US) | Not approved (investigational) | FDA approved (obesity, 2021) | FDA approved (obesity, 2023) |
| Maintenance dose (clinical/approved) | Up to 6.0 mg weekly (Phase 2) | 2.4 mg weekly | Up to 15 mg weekly |
| Best documented weight loss (Phase 2 or pivotal trial) | Approx. 14.9% at 46 weeks (Phase 2) | Approx. 14.9% at 68 weeks (STEP 1 RCT, Wilding et al. 2021) | Approx. 20.9% at 72 weeks (SURMOUNT-1, Jastreboff et al. 2022) |
| MASH / liver fat evidence | Phase 2 signal (GCGR mechanism relevant) | Secondary endpoint data (less direct GCGR mechanism) | Emerging data, GIPR/GLP-1R pathway |
| GI tolerability | Nausea/vomiting common, dose-dependent; GCGR adds complexity | Well-characterized nausea profile across thousands of patients | Similar GI profile to semaglutide, well-characterized |
| Head-to-head RCT vs. others | None published | STEP 8 vs. liraglutide; none vs. survodutide | SURMOUNT-5 vs. semaglutide; none vs. survodutide |
| Where survodutide loses honestly | Survodutide lacks the large Phase 3 safety database, cardiovascular outcomes data, and regulatory approval that semaglutide and tirzepatide have. Its theoretical energy expenditure advantage from GCGR activation is not yet confirmed in a published human energy expenditure RCT. | ||
How to read a survodutide vial and COA
Because survodutide is investigational and not available through a standard pharmacy channel, any vial purchased for research purposes requires careful quality verification. Here is what to require and how to read it.
Minimum COA requirements:
- HPLC purity: Look for greater than 98% purity by reverse-phase HPLC. A result below 95% suggests significant impurity fraction that could include truncated sequences or racemized residues.
- Mass spectrometry confirmation: The observed molecular mass should match the theoretical mass of survodutide within approximately 1 Da. This confirms sequence integrity and rules out gross synthesis errors.
- Lot number: Should appear on both the vial label and the COA. Mismatched lot numbers mean the COA was not generated for the specific material in the vial.
- Endotoxin / LAL testing: For any injectable research compound, endotoxin levels (measured by limulus amebocyte lysate assay) should be reported and below USP limits for parenteral use (less than 5 EU/kg/dose as a general benchmark).
- Storage conditions stated: Lyophilized powder should be specified for storage at 2 to 8 degrees Celsius or colder, protected from light.
Reconstitution math example: If you have a 5 mg lyophilized vial and want a concentration of 1 mg/mL, add 5 mL of bacteriostatic water. Gently swirl, do not vortex (vortexing promotes aggregation). For a 4.8 mg weekly research dose, that would be 4.8 mL of the 1 mg/mL solution per injection. Confirm units carefully: mg vs. mcg errors are the most common reconstitution mistake, and a 1000x dosing error is possible if these are confused.
What degradation looks like: A freshly reconstituted peptide solution should be clear and colorless. Cloudiness, visible particulate matter, yellow or brown tinting, or a gel-like consistency all indicate protein aggregation or chemical degradation. Degraded material should not be used.
What are the side effects at each survodutide dose band?
Published Phase 2 data report that adverse events were predominantly gastrointestinal and followed a clear dose-response relationship. Nausea, vomiting, diarrhea, and decreased appetite were the most frequent reports across all active dose arms. The 6.0 mg arm had higher discontinuation rates due to GI events than the 2.4 mg arm, consistent with the dose-response pattern seen across the GLP-1 drug class.
The glucagon receptor agonism introduces two additional considerations not present with pure GLP-1 agonists. First, fasting glucose may rise slightly in non-diabetic individuals because glucagon normally raises blood glucose between meals and this stimulus is not fully counterbalanced by GLP-1R-mediated insulin release outside of eating. Second, the GCGR pathway in the liver stimulates fatty acid oxidation and can cause changes in lipid panel readings. Neither of these effects has been characterized in a long-term human outcomes study for survodutide specifically.
Serious adverse events reported in Phase 2 were not uniquely attributable to survodutide above the expected background rate, but the trial was not powered or designed to detect rare events. Without Phase 3 data, the long-term cardiovascular, thyroid, and pancreatitis risk profile cannot be fully characterized.
FAQ
What is the typical survodutide dosage used in clinical trials?
Phase 2 trials tested survodutide at doses ranging from 2.4 mg to 6.0 mg administered subcutaneously once weekly, with escalation over multiple weeks. The 4.8 mg and 6.0 mg dose groups produced the most notable weight reduction in the Boehringer Ingelheim Phase 2 obesity trial.
How is survodutide dose escalation structured?
The clinical escalation used in Phase 2 started at a low dose (around 0.3 mg to 0.6 mg) and increased in steps every 4 to 8 weeks to allow GI tolerance, reaching target doses of 2.4 mg, 4.8 mg, or 6.0 mg weekly. Rapid escalation is associated with higher rates of nausea and vomiting.
What weight loss was seen at the highest survodutide dose?
In the Boehringer Ingelheim Phase 2 trial (approximately 387 participants, 46 weeks), the 6.0 mg weekly dose group achieved a mean body weight reduction of approximately 14.9% from baseline. This is directionally competitive with early semaglutide data but Phase 3 results are not yet available.
Is survodutide FDA approved?
No. As of May 2026, survodutide is not FDA approved for any indication. It is an investigational compound in Phase 2 to Phase 3 development by Boehringer Ingelheim for obesity and metabolic dysfunction-associated steatohepatitis (MASH).
What receptor does survodutide act on?
Survodutide is a dual GLP-1 receptor and glucagon receptor agonist. It is a synthetic peptide conjugated to a fatty acid chain for extended half-life, with approximately equal potency at both receptor types in preclinical assays.
What is the half-life of survodutide?
Survodutide has a half-life consistent with once-weekly dosing, estimated at roughly 7 days based on its fatty acid conjugation design, similar to semaglutide. Exact published pharmacokinetic numbers from Phase 1 are not yet widely available in open literature.
What are the most common side effects at clinical doses?
Nausea, vomiting, diarrhea, and decreased appetite are the most commonly reported adverse events, consistent with GLP-1 class effects. Rates were higher at the 6.0 mg dose than at 2.4 mg. Glucagon receptor activity may also affect glycemic control in people without diabetes.
Can survodutide dosage be split or taken daily?
No data supports daily or split dosing. The molecule is designed for weekly subcutaneous injection based on its pharmacokinetics. Splitting doses would not mimic the clinical protocol and could produce unstable plasma levels.
How does survodutide dosage compare to semaglutide dosage?
Semaglutide for obesity (Wegovy) uses weekly doses of 0.25 mg escalating to 2.4 mg. Survodutide doses in Phase 2 were 2 to 2.5 times higher by mass (up to 6.0 mg), reflecting differences in molecular weight, receptor potency distribution, and formulation rather than a simple equivalence.
What does a legitimate survodutide vial COA include?
A credible certificate of analysis should include HPLC purity (ideally greater than 98%), molecular weight confirmation by mass spectrometry, peptide sequence verification, sterility or endotoxin testing, and lot-specific batch number. Absence of any of these is a sourcing red flag.
Is survodutide the same as BI 456906?
Yes. BI 456906 is the internal Boehringer Ingelheim development code for survodutide. Both names refer to the same GLP-1 and glucagon dual receptor agonist compound.
What happens if survodutide is stored incorrectly?
Peptide bonds in survodutide are vulnerable to hydrolysis at elevated temperatures and to oxidation at susceptible residues. Lyophilized powder is more stable than reconstituted solution. Reconstituted peptide should be kept refrigerated and used within a short window to avoid degradation.
Sources
- ClinicalTrials.gov. NCT04667377. "A Study to Test Different Doses of Survodutide in People With Overweight or Obesity." Boehringer Ingelheim. Available at: clinicaltrials.gov
- ClinicalTrials.gov. NCT05066178. "A Study to Test the Effect of Survodutide in People With NASH/MASH." Boehringer Ingelheim. Available at: clinicaltrials.gov
- Boehringer Ingelheim. Phase 2 obesity trial results press release and conference presentation data, published 2023 to 2024. (American Diabetes Association and EASD meeting abstracts).
- Wilding JPH, Batterham RL, Calanna S, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine. 2021;384:989-1002. (STEP 1 trial; semaglutide comparator data.)
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine. 2022;387:205-216. (SURMOUNT-1; tirzepatide comparator data.)
- Finan B, et al. "Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans." Science Translational Medicine. 2013;5(209). (Mechanistic basis for GLP-1/glucagon dual agonism.)
- Drucker DJ. "The Biology of Incretin Hormones." Cell Metabolism. 2006;3(3):153-165. (GLP-1 receptor mechanism reference.)
- United States Pharmacopeia (USP). General Chapter 85: Bacterial Endotoxins Test. (Endotoxin limit reference for parenteral compounds.)
- Lau J, et al. "Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide." Journal of Medicinal Chemistry. 2015;58(18):7370-7380. (Fatty acid conjugation half-life extension mechanism; structural analogy basis.)